Rosmarin, David http://orcid.org/0000-0003-2786-0708
Soliman, Ahmed M. http://orcid.org/0009-0008-8632-1396
Piercy, James http://orcid.org/0000-0001-7015-1021
Marwaha, Simran http://orcid.org/0000-0003-0380-0372
Anderson, Peter http://orcid.org/0000-0002-2171-8228
Camp, Heidi S. http://orcid.org/0009-0003-2632-015X
Funding for this research was provided by:
AbbVie
Article History
Received: 27 March 2024
Accepted: 14 May 2024
First Online: 2 June 2024
Declarations
:
: David Rosmarin has consulted, spoken for, or conducted trials for the following companies: AbbVie, Abcuro, AltruBio, Amgen, Arena, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Galderma, Incyte, Janssen, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, Viela Bio, Zura Bio. James Piercy, Simran Marwaha, and Peter Anderson are employees of Adelphi Real World and were contracted by AbbVie for this study. Ahmed M. Soliman and Heidi S. Camp are full-time employees of AbbVie and may hold AbbVie stock and/or stock options and patents.
: Patients completed a declaration page where they agreed to partake in the completion of the PSC in accordance with HIPAA and equivalent EU guidelines. The DSP fieldwork teams adhered to national data collection regulations and submitted the DSP methodology and fieldwork (including consent forms) to Pearl Institutional Review Board.